Your selection
Innovation / 28.07.2025
Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796.
The capital increase was entered in the commercial register on 25 July 2025 and thus became effective. As a result, the company's share capital increased from € 21,171,932 to € 63,515,796.
The company will report on the exact details of the share split once the technical details have been finalized with the banks.
The share split aims in particular to increase the liquidity of the share and thus facilitate the tradability of Eckert & Ziegler shares.
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Source: Press Release Eckert & Ziegler
Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation
Overview News
News Buch Berlin
Promoting awareness of health research
During a week-long course at the Gläsernes Labor, 24 teenagers delved into genetics, immunology, and allergic disease. The course marked the beginning of a new collaboration with the Max Delbrück Cent...
more ...Targeting sleeping tumor cells
Neuroblastoma, a cancer mainly affecting children, is often difficult to treat. A team led by Jan Dörr and Anton Henssen at the Experimental and Clinical Research Center report in “Cancer Discovery,” ...
more ...Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contrac...
more ...Events Buch Berlin
30.08.2025, 17:00
Blindspot-Konzert #7: WOODEN ELEPHANT – BJÖRK: Homogenic
Mit ihrer außergewöhnlichen Fähigkeit, elektronische Kultalben in akustische Klangwelten zu übersetzen, steht das internationale Streichquintett Wooden Elephant im Zentrum des kommenden Konzerts der B...
more ...09.09.2025, 09:00
From Target to Market - The BBA Biotech & Pharma Summer School
The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.
more ...
